2 Information about loncastuximab tesirine

Marketing authorisation indication

2.1

Loncastuximab tesirine (Zynlonta, Swedish Orphan Biovitrum) is indicated for 'the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.'

Dosage in the marketing authorisation

Price

2.3

The list price for loncastuximab tesirine is £15,200 per 10-mg vial (excluding VAT; company submission). An average course of loncastuximab tesirine per person is £85,562.

2.4

The company has a commercial arrangement. This makes loncastuximab tesirine available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.